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Cancer policymakers, researchers, and advocates have different priorities for 
cancer treatment research and may define ‘value’ of new treatments differently. 
Harmonizing the priorities and values of diverse stakeholders may be neither pos-
sible nor desirable. In November 2012, as part of its Patient Access to Cancer care 
Excellence (PACE) initiative, Lilly Oncology convened a Global Council of opinion 
leaders in cancer research, care, and policy to identify barriers to innovation in 
oncology research and develop strategies to improve cancer care. Participants 
concluded that the cancer policy field lacked tools to visualize these differences 
and to track progress in cancer treatments based on variable sets of values. 
Responding to this need, PACE developed the Continuous Innovation Indicators: 
novel, scientifically rigorous progress trackers designed to increase understand-
ing of continuous innovation in cancer treatments among different stakeholders. 
The Indicators quantify progress in cancer treatments by: 1) mining the literature 
to determine the strength of the evidence supporting each treatment; 2) weight-
ing the analysis according to the audience’s priorities and values; and 3) calcu-
lating Evidence Scores (E-Scores), which are measures of progress based on the 
strength of the evidence weighted by the assigned value. We introduce a flexible 
model to illustrate differing values, show how the values from the model can be 
used to weight the evidence from the scientific literature to obtain E-Scores, and 
demonstrate how assigning different values influences E-Scores. Differentiated 
analyses based on values provided by various stakeholders will help the cancer 
policy field to obtain accurate representations of the complex, stepwise progress 
against different cancers over time. We envision partnerships and collaborations 
to support educational efforts, identification and illustration of policy goals, and 
work in the field of health technology assessments. We will not make this tool 
available to individuals or organizations for the purpose of deriving treatment 
recommendations.
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It is widely accepted that, as well as developing new Clinical Outcome Assessments 
(COAs) for clinical trials, using existing COAs to evaluate treatment benefit from 
the patient perspective is often a more pragmatic, time- and cost-effective strat-
egy. However, the suitability of a COA (whether new or existing) is dependent on 
evidence of content and psychometric validity in a specific context and for spe-
cific concepts of interest. Determining which existing COA is most suitable based 
upon these criteria is particularly challenging when a large pool of instruments 
is available. For example, a recent MEDLINE search for COAs in head and neck 
cancer yielded more than 100 instruments. To shortlist from here, the logical next 
step is to review which COAs have been used (successfully and unsuccessfully) 
by sponsors in previous and ongoing trials. However, there is no clear guidance 
that explains how to identify relevant products or trials and what information to 
review to support measurement selection and ensure regulatory acceptance. Thus 
we outline an approach that is systematic, robust and pragmatic to support the 
selection of an existing COA for inclusion in upcoming studies. The Competitor 
Outcomes Landscape Analysis (COLA) methodology is a four-step approach: 1) 
identify relevant competitor drugs using a global clinical trial database, 2) review 
the Drugs@FDA database and the EMA’s European Public Assessment Reports to 
establish approval status and identify COAs included in labelling, 3) review FDA’s 
Drug Approval Packages to document regulatory decision-making and 4) identify 
COAs included in trial protocols for drugs in development. The COLA approach 
helps sponsors to select the most appropriate COA for studies in a specific popu-
lation and disease area. We believe this framework allows for more confidence, 
transparency and credibility in the decision-making process and as such COLA is 
a systematic approach to support an optimal COA strategy.
PRM146
advanCing MethOds Of hta: OPtiMising MOnitORing tests tO Meet 
value taRgets
McCabe C., Paulden M., Akude P.
University of Alberta, Edmonton, AB, Canada
Optimising the value of monitoring tests is currently under-researched. 
Conventionally, tests are repeated at fixed intervals using a fixed test cut-point 
value. Theory however suggests that diagnostic test performance changes with 
repeated use in any given population. We hypothesize that conventional practice 
may be sub-optimal. A simulation model is built to determine the test cut-point 
and retest interval which maximize population health. A simulated experiment is 
carried out on a hypothetical population of 10,000 patients who are being moni-
tored for disease progression or remission of some chronic disease for a period 
of 6months. a dichotomous test is applied on the population each month for the 
entire monitoring period. The patients are repeatedly stratified into diagnostic 
sub-populations (positive or negative) after each test, using a cut-point value 
between 0 and 1. The test performance and optimal cut-point in each sub-popu-
lation is measured after each repetition. Patients are then allowed only two tests 
within a monitoring period. We allow the retest interval and cut-point value to 
vary simultaneously across sub-populations. Population net health benefit (in 
QALYs) is estimated for all possible intervals and cut-points, and the optimal cut-
point and retest interval is determined. Preliminary results from our hypothetical 
simulation suggests that patients should be initially diagnosed using a cut-point 
of 0.25. Patients with a positive diagnosis should be re-tested after 4 months using 
a cut-point of 0.55, while those with a negative diagnosis should be re-tested after 
2 months using a cut-point of 0.20. The most efficient conventional strategy is 
associated with an expected health loss of 50 QALYs across the population com-
pared to the optimal strategy. Maximising the value of a monitoring test requires a 
dynamic test cut-off with respect to population characteristics based on previous 
test results, and the re-test interval.
dominancy is a key to answer, we aimed to formulate an analytical criterion which 
judges the extended dominancy of a new technology in comparison with the SOC 
and placebo. Methods: Assume the ICER of a new technology is evaluated with 
expected effectiveness Ex and cost Cx, compared to placebo or the SOC, respec-
tively, with a pair of effectiveness and cost: (Ep, Cp) and (Es, Cs), where Ep < Es < 
Ex and Cp < Cs < Cx. Then, regarding an ICER as the slope between two points on 
the cost-effectiveness plane, the concept of extended dominancy was materialized 
through a geometric approach so that the slope of the line connecting between a 
new technology and the SOC should be shallower than that between the SOC to 
placebo. Results: The analytical development resulted in the following criterion: 
if the expected cost Cx is smaller than the value of aEx + b, where a = (Cs - Cp) / (Es - 
Ep) and b = (CpEs - CsEp) / (Es - Ep), then the new technology can be judged as being 
extended dominant to the SOC. It implies the ICER of the new technology compared 
to the SOC must be smaller than that compared to placebo. If Cx is greater than 
aEx + b, the extended dominancy disappears with the ICER to the SOC greater than 
that to placebo. ConClusions: The criterion would be useful for decision makers 
to judge the extended dominancy and further to know the magnitude relationship 
between two ICERs of a new technology compared to the SOC or placebo.
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oBJeCtiVe: To present the concept of the expanded number needed to treat (NNT) as 
a potential decision aid for continuous outcome measures, to show how the expanded 
NNT can be derived from results of health economic analyses, to review some exam-
ples, and to discuss potential benefits and limitations. METHOD: The NNT, calcu-
lated as the inverse of the absolute risk reduction, provides clinicians and patients 
with intuitive risk-benefit information based on natural frequencies as opposed 
to reporting statistics in terms of probabilities, such as relative and absolute risks. 
However, one significant limitation of the NNT is that it only applies to binary out-
comes. Methods have been developed for estimating NNTs for continuous outcome 
measures, for example by dichotomizing outcomes according to whether a minimal 
clinically important difference is achieved. These methods may be appropriate for 
clinical decision making but may not be necessary for continuous outcomes, such 
as LYs and QALYs, when considered from the perspective of a health policy decision 
maker at the societal level. Accordingly, we propose the concept of the expanded 
NNT, calculated as the inverse of the difference in outcomes or, alternatively, as the 
incremental cost-effectiveness ratio divided by the incremental costs. The expanded 
NNT is a measure of clinical benefit, informing decision makers of how many peo-
ple would need to be treated with one intervention versus another to achieve one 
additional unit of outcome (eg, LY or QALY). We review some differences between the 
NNT and expanded NNT, provide some worked examples, and discuss the potential 
benefits and limitations of the expanded NNT. CONCLUSION: The expanded NNT may 
provide policy makers with a more intuitive metric to compare the clinical benefit 
of population level interventions involving LYs and QALYs and is consistent with 
standard methods of health economic decision making.
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Disease simulators model the evolution of biomarkers or clinical events character-
izing the disease in question over different time horizons, populations or treatment 
options. At the core of simulators are inter-connected equations that capture how 
patients’ characteristics impact changes in biomarkers and events over time. Many 
considerations go into the derivation and validation of such equations. Using exam-
ples from the development of an Alzheimer’s disease (AD) simulator, we call attention 
to a few specific issues and provide guidance on how to address these. The first issue 
concerns the parameterization of outcomes; for instance, predicting change from 
baseline versus previous visit, or determining whether a transformation is required. 
A practical consideration in choosing among formulations is the simplicity of the pat-
tern of change over time for each option, which can both enhance the fit and facilitate 
interpretation. Furthermore, one must consider how the effect of treatments on these 
markers is typically reported, so that these can be easily studied in the simulator. A 
more intricate issue lies in correctly capturing the inter-dependence of the various 
outcomes in the simulation without amplifying co-linearity between predictors. For 
instance, in AD, functionality depends on cognitive ability; thus, various measures 
of cognition can be helpful in predicting change in functionality over time. These 
measures of cognitive ability may be highly correlated, but have complimentary 
associations with functionality. High co-linearity can limit the generalizability of 
the equations beyond the source data and over long projection windows, and yield 
illogical predictions. The optimal formulation must balance the relative importance of 
correlated predictors with the relative gain in fit. Finally, we address validation, more 
specifically, the clinical plausibility of individual equation forms and results when 
equations are integrated together, and the propagation of errors as predictions from 
one equation are used to predict other outcomes.
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decrease in medical errors; positive ROI and meeting government expectations for 
healthcare reform (including ACO, PCMH, PQRS, MU). ePRO benefits include: over-
coming paper limitations (illegible patient entries, large amounts of missing data, 
easily destroyed, no time/date stamps); more easily integrated; readiness to analyze; 
higher quality data; easier for sites/sponsors to obtain information; increased effi-
ciency; increased compliance; easier to monitor patient safety; decrease in errone-
ous data; reduction in patient/site burden. Most reasons for increased EMR adoption 
in clinical practice are similar to ePRO benefits for clinical research. Major reasons 
for EMR adoption are positive ROI associated with higher quality data and meet-
ing government expectations. Clinical research still needs to recognize the overall 
positive ROI, since start-up costs are higher with ePRO. ePRO can pose an overall 
positive ROI when looking at the costs savings associated with higher quality data. 
While regulatory authorities recognize ePRO benefits, additional regulatory support 
would also render higher ePRO adoption rate.
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BACkgRound: Systematic reviews (SRs) are critically important to support deci-
sion making in health care. Interest in reliable and quick evidence synthesis has 
sparked development of “rapid reviews” yet no clear consensus exists on what 
these are or what processes they use. The goal of this project was to understand 
and describe practices of conducting rapid reviews. Methods: We searched the 
literature to identify rapid review methods, guidance, and empiric evidence, and 
conducted interviews with organizations that produce rapid reviews to identify 
current practices, and understand the evolution of their programs and products. We 
analyzed the data qualitatively, integrating information gathered from the literature 
and interviews. Results: We identified 36 rapid products from 20 organizations 
(production time, 5 minutes to 8 months). Almost all products used four approaches 
to save time (restricted database searching, inclusion criteria, data abstraction, and 
dual review); with faster products tending to employ more of these approaches. 
Methods also varied by synthesis type, with some products (Inventories) avoiding 
synthesis completely, while others (Rapid reviews) performed syntheses similar to 
full reviews but with limited scope and review to achieve deadlines. Interviews with 
producers provided insight into these variations. Most rapid products are produced 
to support specific decisions in an identified timeframe within the context of a 
close relationship between researcher and end-user. This allows selection of meth-
ods that best fit the decision and timeframe, and helps the end-user understand 
resulting limitations. Almost no empiric evidence exist comparing rapid reviews 
and SRs. ConClusions: Rapid products have tremendous methodological varia-
tion, but categorization based on timeframe or type of synthesis reveals some pat-
terns. This variation in methods results in part from the close relationship between 
reviewer and end-user. Organizations considering production or consumption of 
rapid review products need to consider this context and other factors.
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ResouRCe Modelling: the Missing PieCe oF the htA JigsAW?: Within health 
technology assessment (HTA), cost-effectiveness analysis and budget impact analyses 
have been broadly accepted as important components of decision making. However, 
whilst they address efficiency and affordability, the issue of implementation and 
feasibility has been largely ignored. HTA commonly takes place within a deliberative 
framework that captures issues of implementation and feasibility in a qualitative 
manner. Economic analyses typically ignore the short-term constraints (e.g. beds, 
availability of computed tomography scanners, nurses) that might lead to low levels 
of uptake. We argue that only through a formal quantitative assessment of resource 
constraints can these issues be fully addressed. Analyses that do not consider these 
issues run the risk of recommending technologies that cannot be delivered within 
the expected time frame, or which require higher than expected costs to ensure 
delivery thereby reducing the cost effectiveness of the recommendation. We argue 
that resource modelling is required for uptake to be formally considered by decision 
makers. We define resource modelling as a quantitative assessment of technology 
diffusion, its related resource requirements and capacity constraints. Resource mod-
elling is especially useful if there are significant changes in the amount or type of 
resources needed within the pathway by implementing the new technology. We will 
describe the usefulness of resource modelling along with examples from the litera-
ture. We describe the modelling techniques (discrete event simulation and system 
dynamics) which can capture these resource implications and highlight that these 
analyses can be performed at a national or organisational level. Finally, important 
issues that need to be considered when undertaking resource modelling are described 
before setting out recommendations for the use of resource modelling in HTA. Further 
research should examine the potential use of operational research techniques in the 
assessments of cost effectiveness and feasibility.
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data Cleaning PaPeR Patient RePORted OutCOMe (PRO) data veRsus 
eleCtROniC Patient RePORted OutCOMe (ePRO) data
Ross J., Holzbaur E., Wade M., Rothrock T.
Almac Clinical Technologies, Souderton, PA, USA
This conceptual paper will illustrate the impacts of low quality data, describe the 
requirements of the data cleaning process, compare the data cleaning process for 
paper versus ePRO, and provide recommendations of how ePRO can be implemented 
to decrease the level of effort of data cleaning. Before data can be analyzed, data 
cleaning must occur to ensure high data quality. Low quality data can have major 
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MaRS EXCITE is an innovation in health technology assessment (HTA) where 
industry, academia, and the health system collaborate to design and execute a 
robust evaluation program for innovative medical technologies with high disruptive 
potential that proactively satisfies regulatory and reimbursement decision-mak-
ers requirements. EXCITE compromises five Methodological Centres (MCs) across 
Ontario, Canada with demonstrated excellence in methodologies for designing and 
conducting complex, multi-centre trials and HTAs. The MCs develop the protocol 
collaboratively with industry and experts, and oversee the clinical trials, involv-
ing multiple participating sites. In an attempt to promote consistency in Quality 
Assurance (QA) amongst MCs and participating sites for EXCITE studies, EXCITE 
has developed SOPs, through the Clinical Trials Methodology Committee, that relate 
exclusively to the unique collaboration with the MCs. These were developed through 
an analysis of host institution SOPs and developing overarching SOPs that were 
either unique to the EXCITE QA program, or where deemed appropriate though 
lacking from some host institutions. This harmonization of SOPs across the five 
current EXCITE MCs has allowed EXCITE to address one of the main goals of clinical 
trial QA that is integrity of data. The second goal of clinical trial QA, patient safety, 
is achieved through the Safety Advisory committee, which sets safety standards 
that must be adhered to by the MCs evaluating the technologies. The committee 
reviews all protocols to ensure that patient safety issues are addressed,makes rec-
ommendations for protocol changes as necessary and may also mandate training 
requirements to ensure competency in utilization of any medical technology under-
going testing in the EXCITE program. Therefore, MaRS EXCITE was able to deploy 
a collaborative platform to harmonize the QA processes across five independent 
academic methodological centres in order to conduct efficient and effective clini-
cal trials that are used in evaluating disruptive medical technologies in an effort to 
optimize patient outcomes.
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There is increasing interest in innovation in the development and validation of 
clinical outcome assessments (COAs), fuelled by the need to demonstrate robust 
evidence of content validity for regulatory approval with ever increasing budget 
and time constraints. Traditionally, qualitative research methods have relied upon 
standard one-one interview and focus groups techniques; however these may not 
always be appropriate, particularly for patients with communication difficulties 
or in pediatric populations or for sensitive research areas. Creative methodolo-
gies can be a pragmatic way to elicit patient-driven insights and identify appropri-
ate outcomes in special populations. There is a well-established literature base 
exploring the use of creative methodologies in social research and many of these 
approaches can be readily applied to outcomes research. We have reviewed a vari-
ety of creative methods and purposively selected the most valuable approaches to 
create a toolkit of methods to advance the development of patient-centred COAs. 
The toolkit of creative methods is discussed in context of: 1) disease and clinical 
characteristics, 2) patient demographics and 3) research objectives. Integration of 
creative methodologies throughout the COA development process serves to develop 
patient-driven insights for concept elicitation and item generation. By advancing 
elicitation techniques (e.g. visual elicitation), and ecological evidence generation 
(e.g. video diaries) participants’ have the power and freedom to show how they per-
ceive and experience their condition, rather than reliance on verbal report. Creative 
methodologies can be used to demonstrate reliable, valid and content rich data 
for a variety of populations and contexts of use. There are exciting opportunities 
to build upon existing practice and advance creative research approaches in this 
field. Integrating such methodologies generates patient insight to underpin content 
development for COAs ensuring they are developed with an evolving fit for pur-
pose approach. The application of such methods for regulatory COA development 
requires further exploration.
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with teChnOlOgy use
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In clinical practice, Electronic Medical Record (EMR) adoption has rapidly increased 
over recent years. In 2013, it was estimated that 78.4% of physician-based practices 
use some type of EMR system (as reported by National Center for Health Statistics). 
In clinical research, electronic Patient Reported Outcomes (ePRO) adoption is mov-
ing slower–where it is estimated that less than half of PRO studies use ePRO. This 
conceptual paper compares EMR benefits of clinical practice with ePRO benefits of 
clinical research and provides recommendations of how clinical research can follow 
clinical practice in benefiting from technology. EMR benefits include: overcoming 
paper limitations (illegible clinician notes, large amounts of missing information, 
easily destroyed, no time/date traceability and whose viewed/accessed); improved 
integrations with other practices/facilities; readiness to analyze; higher quality data; 
easier to obtain payment; easier to provide information to insurance providers; 
increased efficiency; increased compliance; increased quality of care/patient safety; 
